On November 13, Caris Life Sciences, Inc. fell 4.19% in Regular Trading, trading at $23.09 per share, with turnover of $5.2361 million.
The move followed continued post-earnings selling pressure even after the company reported third-quarter results above expectations and raised full-year revenue guidance.
Caris Life Sciences, Inc. previously reported Q3 EPS of $0.05, above consensus expectations of $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million forecast. The company also lifted full-year revenue guidance to $1.04 billion to $1.05 billion. Even so, EPS was below the prior-year level of $0.08, and recent analyst views remained mixed, with Buy and Neutral ratings both in place, suggesting investors remain cautious on valuation and the durability of growth.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments